Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

434 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Quality of life changes in patients undergoing treatment for hepatocellular carcinoma.
Chie WC, Yu F, Li M, Baccaglini L, Blazeby JM, Hsiao CF, Chiu HC, Poon RT, Mikoshiba N, Al-Kadhimi G, Heaton N, Calara J, Collins P, Caddick K, Costantini A, Vilgrain V, Chiang C. Chie WC, et al. Among authors: poon rt. Qual Life Res. 2015 Oct;24(10):2499-506. doi: 10.1007/s11136-015-0985-8. Epub 2015 May 6. Qual Life Res. 2015. PMID: 25943170
Differences in health-related quality of life between European and Asian patients with hepatocellular carcinoma.
Chie WC, Blazeby JM, Hsiao CF, Chiu HC, Poon RT, Mikoshiba N, Al-Kadhim G, Heaton N, Calara J, Collins P, Caddick K, Costantini A, Vilgrain V; Chieh Chiang, on behalf of the EORTC Quality of Life Group. Chie WC, et al. Among authors: poon rt. Asia Pac J Clin Oncol. 2017 Oct;13(5):e304-e311. doi: 10.1111/ajco.12464. Epub 2016 Apr 1. Asia Pac J Clin Oncol. 2017. PMID: 27038366
International cross-cultural field validation of an European Organization for Research and Treatment of Cancer questionnaire module for patients with primary liver cancer, the European Organization for Research and Treatment of Cancer quality-of-life questionnaire HCC18.
Chie WC, Blazeby JM, Hsiao CF, Chiu HC, Poon RT, Mikoshiba N, Al-Kadhimi G, Heaton N, Calara J, Collins P, Caddick K, Costantini A, Vilgrain V, Trinquart L, Chiang C; EORTC Quality of Life Group. Chie WC, et al. Among authors: poon rt. Hepatology. 2012 Apr;55(4):1122-9. doi: 10.1002/hep.24798. Epub 2012 Mar 1. Hepatology. 2012. PMID: 22105642
Ramucirumab as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib: Patient-focused outcome results from the randomised phase III REACH study.
Chau I, Peck-Radosavljevic M, Borg C, Malfertheiner P, Seitz JF, Park JO, Ryoo BY, Yen CJ, Kudo M, Poon R, Pastorelli D, Blanc JF, Chung HC, Baron AD, Okusaka T, Bowman L, Cui ZL, Girvan AC, Abada PB, Yang L, Zhu AX. Chau I, et al. Eur J Cancer. 2017 Aug;81:17-25. doi: 10.1016/j.ejca.2017.05.001. Epub 2017 Jun 4. Eur J Cancer. 2017. PMID: 28591675 Clinical Trial.
Molecular pathways in hepatocellular carcinoma.
Pang R, Tse E, Poon RT. Pang R, et al. Among authors: poon rt. Cancer Lett. 2006 Aug 28;240(2):157-69. doi: 10.1016/j.canlet.2005.08.031. Epub 2005 Oct 17. Cancer Lett. 2006. PMID: 16239065 Review.
Biology of hepatocellular carcinoma.
Pang RW, Joh JW, Johnson PJ, Monden M, Pawlik TM, Poon RT. Pang RW, et al. Among authors: poon rt. Ann Surg Oncol. 2008 Apr;15(4):962-71. doi: 10.1245/s10434-007-9730-z. Epub 2008 Jan 31. Ann Surg Oncol. 2008. PMID: 18236113 Review.
434 results